Cmed to Expand US Geographical Presence Opening New Offices in Boston and California

HORSHAM, England--Cmed Group announces revisions to its US geographical presence that will bring closer alignment with the needs of its growing client base in Boston and California. A new office is being opened in Massachusetts Avenue, Boston, and similarly a new office location is being established in the Bay area of San Francisco.

These new offices will compliment Cmed's US operations hub which over recent years was moved from New Jersey to Durham, North Carolina, and which expanded into larger office premises in November 2012. Today Cmed also announced its Durham office will become its US Headquarters. Support functions such as Finance and Human Resources will transfer from its New Jersey based office, which will be closed. Operations and ongoing projects will not be affected.

Cmed Group CEO, Dr. David Connelly said "our new US locations are in response to listening to our clients and it aligns Cmed more closely with two pre-eminent sites of biotech and pharma development. Having invested heavily in recent years in building our expertise and capabilities in developing and delivering early phase clinical development, it seemed a natural progression to forge even closer links with our clients in these areas as we strive to help them execute their clinical strategies as quickly and as cost effectively as possible."

Through the coupling of full service trial delivery teams and trusted technology, Cmed has a proven track record of helping the biopharmaceutical industry design and deliver both innovative and traditional early phase I to IIb clinical trials, as well as increasingly being asked by clients to take on their phase III projects.

Cmed has seen accelerating demand for strategic advice and drug development consulting, both in terms of study design and CDP development, and therefore has significantly expanded its in-house Drug Development Consulting, Regulatory & Medical Affairs Group, as well as expanding its other operational capabilities.

- ends -

About Cmed Group

Cmed Group is an innovative clinical trials services and advanced software provider which includes two divisions: Cmed Clinical Services, a full-service clinical research organization, and Cmed Technology, an eClinical technology provider.

About Cmed Clinical Services

Cmed Clinical Services is a long-established, flexible CRO offering project management, clinical monitoring, data management, biostatistics, medical affairs, regulatory, consulting, and medical writing services. While Cmed's area of specialization is the design and delivery of both innovative and traditional phase I to IIb clinical trials, Cmed increasingly uses its experience and capabilities for existing clients phase III programs and for functional service provision of biometrics.

About Cmed Technology

Cmed Technology, an eClinical technology provider, offers Timaeus: a single platform for electronic trial design, paper and electronic data capture, monitoring, coding, data management and reporting. The Timaeus eClinical platform is designed to respond on-demand to the needs of investigators, data managers and study teams. Timaeus' unique architecture uses advanced distributed cloud computing and mobile technologies to provide the freedom to manage any type of data, for any protocol, anywhere. Timaeus has been used in every phase of clinical research – including early phase, pivotal and late phase studies as well as in globally established and emerging markets.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.